{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:23:01Z","timestamp":1785338581903,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Impact Fund from Hong Kong Metropolitan University"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Prednisolone\/prednisone coadministration with abiraterone may explain abiraterone-related increase in cardiovascular risk. We explored this postulation and glucocorticoid\u2019s association with cardiovascular risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5\u2009mg (ABI\u2009+\u2009P5) or 10\u2009mg (ABI\u2009+\u2009P10) daily total prednisolone\/prednisone were followed up for major adverse cardiovascular events (MACE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We analyzed 933 patients. ABI\u2009+\u2009P10, but not enzalutamide, had higher risk of MACE than ABI\u2009+\u2009P5. Cumulative glucocorticoid dose before enzalutamide\/abiraterone initiation was associated with MACE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Prednisolone\/prednisone coadministration with abiraterone likely contributed to abiraterone-related increased cardiovascular risk. Prevalent cumulative glucocorticoid dose was associated with cardiovascular risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41391-024-00889-x","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:03:25Z","timestamp":1725969805000},"page":"516-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-2393","authenticated-orcid":false,"given":"Jeffrey Shi Kai","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-1598","authenticated-orcid":false,"given":"Yan Hiu Athena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-9390","authenticated-orcid":false,"given":"Chi Ho","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ka Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-0889","authenticated-orcid":false,"given":"Edward Christopher","family":"Dee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenrick","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-1253","authenticated-orcid":false,"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1723-9646","authenticated-orcid":false,"given":"Chi Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"889_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol"},{"key":"889_CR2","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16:e645\u2013e653.","journal-title":"Clin Genitourin Cancer"},{"key":"889_CR3","doi-asserted-by":"publisher","unstructured":"Lee YHA, Hui JMH, Leung CH, Tsang CTW, Hui K, Tang P, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis 2023. https:\/\/doi.org\/10.1038\/s41391-023-00757-0.","DOI":"10.1038\/s41391-023-00757-0"},{"key":"889_CR4","doi-asserted-by":"publisher","unstructured":"Wu D, Nam RHK, Leung KSK, Waraich H, Purnomo AF, Chou OHI et al. Population-based clinical studies using routinely collected data in Hong Kong, China: a systematic review of trends and established local practices. Cardiovasc Innov Appl. 2023; 8. https:\/\/doi.org\/10.15212\/CVIA.2023.0073.","DOI":"10.15212\/CVIA.2023.0073"},{"key":"889_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.822375","volume":"12","author":"PY Li","year":"2022","unstructured":"Li PY, Lu YH, Chen CY. Comparative effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan. Front Oncol. 2022;12:822375.","journal-title":"Front Oncol"},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2006.05.019","volume":"192","author":"C Varas-Lorenzo","year":"2007","unstructured":"Varas-Lorenzo C, Rodriguez LAG, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192:376\u201383.","journal-title":"Atherosclerosis"},{"key":"889_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2017;377:352\u201360.","journal-title":"N. Engl J Med"},{"key":"889_CR9","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol J Am Soc Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"889_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/cncr.31836","volume":"125","author":"RR McKay","year":"2019","unstructured":"McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, et al. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019;125:524\u201332.","journal-title":"Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00889-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:03:28Z","timestamp":1748358208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1038\/s41391-024-00889-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ECD is funded in part through the Cancer Center Support Grant from the National Cancer Institute (P30 CA008748). GT is supported by a Research Impact Fund from Hong Kong Metropolitan University (Project Reference No. RIF\/2022\/2.2). All other authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The need for patient consent was waived by the Joint Chinese University of Hong Kong\u2014New Territories East Cluster Clinical Research Ethics Committee due to the retrospective nature of this study and the use of deidentified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}